diaDexus, Inc. is reiterating its guidance of total revenues in the range of $26 to $28 million for 2014. Product sales revenue of the PLAC ELISA Kit have begun to stabilize following the previously disclosed industry-wide impact from guidance issued to cardiovascular testing facilities in June 2014. Total revenue includes service revenue from the $4.8 million service agreement with GSK, of which $3.6 million was reported in the first nine months of 2014.